1. Home
  2. IRD vs SPCB Comparison

IRD vs SPCB Comparison

Compare IRD & SPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • SPCB
  • Stock Information
  • Founded
  • IRD 2018
  • SPCB 1988
  • Country
  • IRD United States
  • SPCB Israel
  • Employees
  • IRD N/A
  • SPCB N/A
  • Industry
  • IRD
  • SPCB Semiconductors
  • Sector
  • IRD
  • SPCB Technology
  • Exchange
  • IRD NYSE
  • SPCB Nasdaq
  • Market Cap
  • IRD 36.1M
  • SPCB 31.4M
  • IPO Year
  • IRD N/A
  • SPCB N/A
  • Fundamental
  • Price
  • IRD $1.15
  • SPCB $8.80
  • Analyst Decision
  • IRD Strong Buy
  • SPCB Strong Buy
  • Analyst Count
  • IRD 1
  • SPCB 1
  • Target Price
  • IRD $8.00
  • SPCB $18.00
  • AVG Volume (30 Days)
  • IRD 154.1K
  • SPCB 774.9K
  • Earning Date
  • IRD 02-19-2025
  • SPCB 11-14-2024
  • Dividend Yield
  • IRD N/A
  • SPCB N/A
  • EPS Growth
  • IRD N/A
  • SPCB N/A
  • EPS
  • IRD N/A
  • SPCB 1.02
  • Revenue
  • IRD $8,381,000.00
  • SPCB $26,843,000.00
  • Revenue This Year
  • IRD N/A
  • SPCB $6.72
  • Revenue Next Year
  • IRD $29.37
  • SPCB $16.91
  • P/E Ratio
  • IRD N/A
  • SPCB $8.59
  • Revenue Growth
  • IRD N/A
  • SPCB 5.23
  • 52 Week Low
  • IRD $0.81
  • SPCB $2.55
  • 52 Week High
  • IRD $2.77
  • SPCB $18.95
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • SPCB 46.90
  • Support Level
  • IRD N/A
  • SPCB $9.21
  • Resistance Level
  • IRD N/A
  • SPCB $11.43
  • Average True Range (ATR)
  • IRD 0.00
  • SPCB 1.74
  • MACD
  • IRD 0.00
  • SPCB -0.67
  • Stochastic Oscillator
  • IRD 0.00
  • SPCB 1.64

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT and Connectivity, which is the key revenue driver; and Cyber Security. Besides, it also offers a wide range of solutions that include national ID registries, e-passports, biometric visas, automated fingerprint identification systems, digitized driver's licenses, and electronic voter registration and election management using the common platform. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and the Asia Pacific.

Share on Social Networks: